免疫诺姆
IMNM
16.47
-0.93
-5.34%
免疫诺姆
US · IMNM
#2671 按市值排名
上市于 2020
16.47
-0.93
-5.34%
实时 - 追踪5344个代码 - 心跳于407秒前
· 2026-10-16 20:01
✦ 量化股权信号 计算方式说明
减持
- 机构持股总比例下降了0.2个百分点。
机构持股
- 机构持股比例
- 110.93% -0.16pp
- 机构数量
- 248
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund86.33%
Hedge Fund11.25%
VC/PE Fund4.59%
Public Company4.50%
Private Company3.74%
Individual/Insider1.15%
Government Pension Fund0.31%
Insurance Company0.12%
主要股东 截至 2026-06-30
T. Rowe Price Group, Inc.
18.89% · 21.45M 股
FMR
14.96% · 16.99M 股
BlackRock
7.75% · 8.81M 股
State Street Global Advisors
4.84% · 5.49M 股
Vanguard Capital Management, LLC
4.67% · 5.31M 股
Wellington Management Group
4.59% · 5.21M 股
Redmile Group, LLC
4.32% · 4.91M 股
Sirenia Capital Management LP
4.25% · 4.83M 股
PRIMECAP Management Company
4.03% · 4.58M 股
Driehaus Capital Management LLC
3.83% · 4.35M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 31次买入 · 19次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Clay Siegall | Chairperson & CEO | 0.61% |
| Philip Wagenheim | Director | 0.30% |
| Isaac Barchas | Lead Independent Director | 0.08% |
| Max Rosett | Officer | 0.05% |
| Jean-Jacques Bienaime | Director | 0.04% |
| Philip Tsai | Chief Technology Officer | 0.04% |
| Jack Higgins | Chief Scientific Officer | 0.02% |
| Robert Lechleider | Chief Medical Officer | 0.01% |
| Sandra Stoneman | Chief Legal Officer | 0.00% |
| James Boylan | Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-10 | Jack Higgins | Chief Scientific Officer | Other Disposition | -4,000 | -- |
| 2026-09-10 | Jack Higgins | Chief Scientific Officer | Derivative Exercise and Sale | -18,000 | $1.35–25.32 |
| 2026-08-11 | Isaac Barchas | Lead Independent Director | Automatic Disposition | -11,048 | $27.25 |
| 2026-08-03 | Kinney Horn | Chief Business Officer | Derivative Exercise and Sale | -90,616 | $10.60–25.09 |
| 2026-07-22 | Clay Siegall | Chairperson & CEO | Other Acquisition | +180,000 | -- |
| 2026-07-22 | Clay Siegall | Chairperson & CEO | Other Derivative Acquisition | +360,000 | $22.01 |
| 2026-07-22 | Jack Higgins | Chief Scientific Officer | Other Acquisition | +38,250 | -- |
| 2026-07-22 | Jack Higgins | Chief Scientific Officer | Other Derivative Acquisition | +76,500 | $22.01 |
| 2026-07-22 | Robert Lechleider | Chief Medical Officer | Other Acquisition | +54,000 | -- |
| 2026-07-22 | Robert Lechleider | Chief Medical Officer | Other Derivative Acquisition | +108,000 | $22.01 |
| 2026-07-22 | Sandra Stoneman | Chief Legal Officer | Other Acquisition | +38,250 | -- |
| 2026-07-22 | Sandra Stoneman | Chief Legal Officer | Other Derivative Acquisition | +76,500 | $22.01 |
| 2026-07-22 | Kinney Horn | Chief Business Officer | Other Acquisition | +31,250 | -- |
| 2026-07-22 | Kinney Horn | Chief Business Officer | Other Derivative Acquisition | +62,500 | $22.01 |
| 2026-07-22 | Max Rosett | Officer | Other Acquisition | +47,250 | -- |
| 2026-07-22 | Max Rosett | Officer | Other Derivative Acquisition | +94,500 | $22.01 |
| 2026-07-22 | Philip Tsai | Chief Technology Officer | Other Acquisition | +38,250 | -- |
| 2026-07-22 | Philip Tsai | Chief Technology Officer | Other Derivative Acquisition | +76,500 | $22.01 |
| 2026-07-06 | Kinney Horn | Chief Business Officer | Derivative Exercise and Sale | -1,092 | $12.92–25.00 |
| 2026-07-01 | Robert Lechleider | Chief Medical Officer | Derivative Exercise and Sale | -55,000 | $8.73–23.44 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:01:17 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
免疫诺姆 讨论区 0 条评论